BIOLOGY REPORTS

Published: 08 September 2010

Fungal echinocandin resistance

Carol A Munro

Address: Aberdeen Fungal Group, School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK

Email: c.a.munro@abdn.ac.uk

F1000 Biology Reports 2010, **2**:66 (doi:10.3410/B2-66)

The electronic version of this article is the complete one and can be found at: http://f1000.com/reports/biology/content/2/66

Abstract

Echinocandins are the most recent introduction to the antifungal armamentarium and target the synthesis of β-(1,3)-glucan, the major structural polysaccharide of the fungal cell wall. Mechanisms have been identified that reduce the efficacy of the echinocandins: mutations of the Fks subunit of the target enzyme complex or a compensatory increase in the production of chitin, the second structural cell wall polysaccharide.

Introduction and context

Caspofungin was the first echinocandin approved for clinical use, followed by anidulafungin and micafungin [1]. Echinocandins are cyclic lipopeptides that target the fungal cell wall by inhibiting β-(1,3)-glucan synthesis [2]. β-(1,3)-glucan is synthesized by a protein complex composed of an integral membrane protein catalytic subunit, Fks, and a regulatory subunit, the Rho1 GTPase, which also regulates protein kinase C (PKC) [3,4]. Most fungi have a number of alternative Fks subunits. Echinocandins are effective against a range of fungal human pathogens and are fungicidal against a number of *Candida* species, including *Candida albicans*. In the case of the filamentous mould *Aspergillus fumigatus*, echinocandins are fungicidal against actively growing hyphal tips but are less effective against non-growing subapical cells [5].

Major recent advances

Although echinocandins are highly efficacious in the treatment of invasive fungal infections and now are used as first-line therapies in many hospitals, several examples of clinical failures due to breakthrough infections have been reported over the last few years [6]. Lab-based studies with *C. albicans* identified dominant mutations in the target protein Fks1, the catalytic subunit of β-(1,3)-glucan synthase which conferred acquired echinocandin resistance [7]. The *C. albicans* Fks1 mutations mapped onto two hotspot regions at amino acids 641-649 and 1345-1365. The same hotspot mutations were identified in clinical isolates from patients who failed or responded poorly to echinocandin therapy, and the *in vivo* echinocandin resistance of these isolates was validated in a systemic candidiasis murine model [7]. Acquired mutations in *FKS1* and *FKS2* genes have now been identified in a wide range of *Candida* species and *A. fumigatus* [8-10]. Sequencing the *FKS* genes from fungi cultured from echinocandin-treated patients with clinical failure due to breakthrough infections has identified mutations in some but not all of the isolates [6,11]. In general, the prevalence of Fks mutations in geographically diverse clinical isolates of several *Candida* species remains low [12]. β-(1,3)-glucan synthase kinetic assays have shown that the sensitivity of the mutated glucan synthase to caspofungin is reduced, resulting in an increased inhibition constant (K_i) [13,14].

Candida parapsilosis and *Candida guilliermondii* have a reduced susceptibility to echinocandins, and this susceptibility is thought to result from naturally occurring polymorphisms in the Fks1p hotspot region which match the acquired mutations identified in echinocandin-resistant isolates of other species [15-17]. Hotspot mutations are more likely to confer resistance to caspofungin than to anidulafungin and micafungin and in many cases result in higher minimum inhibitory concentrations

(MICs) for caspofungin than for the other two [12,14]. However, differences in the potency of the three echinocandin drugs observed *in vitro* diminish in the presence of 50% serum and therefore cross-resistance would occur *in vivo* [18].

Another mechanism that results in reduced echinocandin susceptibility *in vitro* is the activation of cell wall salvage or compensatory pathways (the PKC cell integrity pathway in particular) [19,20], which result in elevated chitin levels. Treatment of *C. albicans in vitro* with sub-MIC caspofungin activates chitin synthesis, and reciprocally cells that have higher cell wall chitin are less susceptible to caspofungin [19,21]. Elevated chitin appears to be an adaptive response to growth in the presence of echinocandins in an attempt to maintain cell wall integrity, and subsequent growth in the absence of drug restores chitin to wild-type levels. Therefore, this is an example of a drug tolerance mechanism rather than resistance. In addition to the importance of the PKC pathway in the response to echinocandins, the Ca^{2+}/calcineurin signaling pathway plays a role as genetic or pharmaceutical blockade of that pathway renders *C. albicans* and *A. fumigatus* hypersensitive to echinocandins [19,21]. The chaperone protein Hsp90, acting through its client protein calcineurin, has also been implicated in the regulation of echinocandin resistance [22]. As Ca^{2+}/calcineurin in turn regulates chitin synthesis [23] and cell wall biogenesis, there are intriguing connections between Hsp90, cell wall and membrane stress, and drug resistance and tolerance.

Future directions

To date, fungal echinocandin resistance does not seem to be a major cause for concern in the treatment of patients with invasive mycoses [24]. However, there is increasing evidence of natural and acquired resistance resulting in recalcitrant life-threatening infections and clinical failure. The reduced susceptibility of fungal cells with elevated chitin requires further investigation to determine whether this phenomenon, observed *in vitro*, also occurs when infected patients are exposed to sub-MIC echinocandin doses. Within a population, there is a subset of cells with higher-than-average chitin levels [19] and it has yet to be determined whether these can persist in the presence of echinocandin treatment and out grow, resulting in a drug-tolerant population. Fungal azole antifungal resistance is dependent on a number of different mechanisms that include upregulation of drug efflux pumps as well as mutation of the drug target [25]. Chromosomal rearrangements and specifically the generation of an isochromosome of the left arm of chromosome 5 also result in azole resistance in *C. albicans* [26,27]. Genome-wide population studies have been used to map the evolution of azole resistance in *Saccharomyces cerevisiae* [28] and *C. albicans* [29]. Similar population studies to look at the evolution of echinocandin resistance would be informative to assess the relative contributions of acquisition of Fks point mutations and activation of chitin biosynthesis as resistance and tolerance mechanisms and to identify alternative factors and pathways that play a role in decreased echinocandin susceptibility.

Abbreviations

MIC, minimum inhibitory concentration; PKC, protein kinase C.

Competing interests

The author declares that she has no competing interests.

References

1. Denning DW: **Echinocandin antifungal drugs.** *Lancet* 2003, **362:**1142-51.
2. Douglas CM, D'Ippolito JA, Shei GJ, Meinz M, Onishi J, Marrinan JA, Li W, Abruzzo GK, Flattery A, Bartizal K, Mitchell A, Kurtz MB: **Identification of the *FKS1* gene of *Candida albicans* as the essential target of 1,3-beta-D-glucan synthase inhibitors.** *Antimicrob Agents Chemother* 1997, **41:**2471-9.
3. Douglas CM, Foor F, Marrinan JA, Morin N, Nielsen JB, Dahl AM, Mazur P, Baginsky W, Li W, El-Sherbeini M, Clemas JA, Mandala SM, Frommer BR, Kurtz MB: **The *Saccharomyces cerevisiae FKS1* (*ETG1*) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase.** *Proc Natl Acad Sci U S A* 1994, **91:**12907-11.
4. Qadota H, Python CP, Inoue SB, Arisawa M, Anraku Y, Zheng Y, Watanabe T, Levin DE, Ohya Y: **Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-beta-glucan synthase.** *Science* 1996, **272:**279-81.
5. Bowman JC, Hicks PS, Kurtz MB, Rosen H, Schmatz DM, Liberator PA, Douglas CM: **The antifungal echinocandin caspofungin acetate kills growing cells of *Aspergillus fumigatus in vitro*.** *Antimicrob Agents Chemother* 2002, **46:**3001-12.
6. Walker LA, Gow NA, Munro CA: **Fungal echinocandin resistance.** *Fungal Genet Biol* 2010, **47:**117-26.
7. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS: **Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical *Candida* sp. isolates.** *Antimicrob Agents Chemother* 2005, **49:**3264-73.
8. Garcia-Effron G, Chua DJ, Tomada JR, Dipersio J, Perlin DS, Ghannoum M, Bonilla H: **Novel *FKS* mutations associated with echinocandin resistance in *Candida* species.** *Antimicrob Agents Chemother* 2010, **54:**2225-7.
9. Perlin DS: **Resistance to echinocandin-class antifungal drugs.** *Drug Resist Updat* 2007, **10:**121-30.
10. Arendrup MC, Garcia-Effron G, Buzina W, Mortensen KL, Reiter N, Lundin C, Jensen HE, Lass-Florl C, Perlin DS, Bruun B: **Breakthrough *Aspergillus fumigatus* and *Candida albicans* double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.** *Antimicrob Agents Chemother* 2009, **53:**1185-93.
11. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD: **Breakthrough invasive candidiasis in patients on micafungin.** *J Clin Microbiol* 2010, **48:**2373-80.
12. Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, Pfaller MA: **Low prevalence of fks1 hot spot 1 mutations in a**

worldwide collection of Candida strains. *Antimicrob Agents Chemother* 2010, **54:**2655-9.

13. Garcia-Effron G, Park S, Perlin DS: **Correlating echinocandin MIC and kinetic inhibition of *fks1* mutant glucan synthases for *Candida albicans*: implications for interpretive breakpoints.** *Antimicrob Agents Chemother* 2009, **53:**112-22.

14. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS: **Effect of *Candida glabrata FKS1* and *FKS2* mutations on echinocandin sensitivity and kinetics of 1,3-(beta)-D-glucan synthase: implication for the existing susceptibility breakpoint.** *Antimicrob Agents Chemother* 2009, **53:**3690-9.

15. Barchiesi F, Spreghini E, Tomassetti S, Della VA, Arzeni D, Manso E, Scalise G: **Effects of caspofungin against *Candida guilliermondii* and *Candida parapsilosis*.** *Antimicrob Agents Chemother* 2006, **50:**2719-27.

F1000 Factor 6.0 *Must Read*
Evaluated by Annette Fothergill 15 Aug 2006

16. Canton E, Peman J, Sastre M, Romero M, Espinel-Ingroff A: **Killing kinetics of caspofungin, micafungin, and amphotericin B against *Candida guilliermondii*.** *Antimicrob Agents Chemother* 2006, **50:**2829-32.

17. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS: **A naturally-occurring Fks1p proline to alanine amino acid change in *Candida parapsilosis, Candida orthopsilosis* and *Candida metapsilosis* accounts for reduced echinocandin susceptibility.** *Antimicrob Agents Chemother* 2008, **52:**2305-12.

F1000 Factor 6.0 *Must Read*
Evaluated by Ana Espinel-Ingroff 29 May 2008

18. Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS: **Serum differentially alters the antifungal properties of echinocandin drugs.** *Antimicrob Agents Chemother* 2007, **51:**2253-6.

19. Reinoso-Martin C, Schuller C, Schuetzer-Muehlbauer M, Kuchler K: **The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling.** *Eukaryot Cell* 2003, **2:**1200-10.

20. Fortwendel JR, Juvvadi PR, Pinchai N, Perfect BZ, Alspaugh JA, Perfect JR, Steinbach WJ: **Differential effects of inhibiting chitin and 1,3-(beta)-D-glucan synthesis in ras and calcineurin mutants of *Aspergillus fumigatus*.** *Antimicrob Agents Chemother* 2009, **53:**476-82.

21. Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA: **Stimulation of chitin synthesis rescues *Candida albicans* from echinocandins.** *PLoS Pathog* 2008, **4:**e1000040.

F1000 Factor 6.0 *Must Read*
Evaluated by S Arun Balajee 17 Jun 2008

22. Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, Cowen LE: **Hsp90 governs echinocandin resistance in the pathogenic yeast *Candida albicans* via calcineurin.** *PLoS Pathog* 2009, **5:**e1000532.

F1000 Factor 6.0 *Must Read*
Evaluated by Joe Heitman 11 Aug 2009

23. Munro CA, Selvaggini S, de Bruijn I, Walker L, Lenardon MD, Gerssen B, Milne S, Brown AJ, Gow NA: **The PKC, HOG and Ca^{2+} signalling pathways co-ordinately regulate chitin synthesis in *Candida albicans*.** *Mol Microbiol* 2007, **63:**1399-413.

24. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ: ***In vitro* susceptibility of invasive isolates of *Candida* spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.** *J Clin Microbiol* 2008, **46:**150-6.

F1000 Factor 3.0 *Recommended*
Evaluated by Ana Espinel-Ingroff 14 Feb 2008

25. Sanglard D, Odds FC: **Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences.** *Lancet Infect Dis* 2002, **2:**73-85.

26. Selmecki A, Forche A, Berman J: **Aneuploidy and isochromosome formation in drug-resistant *Candida albicans*.** *Science* 2006, **313:**367-70.

27. Selmecki A, Gerami-Nejad M, Paulson C, Forche A, Berman J: **An isochromosome confers drug resistance *in vivo* by amplification of two genes, *ERG11* and *TAC1*.** *Mol Microbiol* 2008, **68:**624-41.

28. Anderson JB, Sirjusingh C, Parsons AB, Boone C, Wickens C, Cowen LE, Kohn LM: **Mode of selection and experimental evolution of antifungal drug resistance in *Saccharomyces cerevisiae*.** *Genetics* 2003, **163:**1287-98.

29. Cowen LE, Nantel A, Whiteway MS, Thomas DY, Tessier DC, Kohn LM, Anderson JB: **Population genomics of drug resistance in *Candida albicans*.** *Proc Natl Acad Sci U S A* 2002, **99:**9284-99.

F1000 Factor 3.0 *Recommended*
Evaluated by Paula Sundstrom 15 Nov 2002